SLITRK6 and hearing loss disorder: NT-3 delivery has been attempted in model animals [20]–[22] with the aim of clinical treatment of hearing impairment, and it would be beneficial to further clarify the mechanism of Slitrk6 action in development of the inner ear and auditory signal processing.